Advertisement

Topics

FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIBRA (emicizumab-kxwh) in Hemophilia a Without Inhibitors

01:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Designation based on Phase III HAVEN 3 study demonstrating HEMLIBRA prophylaxis significantly reduced bleeds compared to no prophylaxis – – First medicine to show superior efficacy compared to prior factor VIII ...

Other Sources for this Article

Genentech
Media Contact:
Liz Walmsley, 650-467-6800
or
Advocacy Contact:
Sonali Chopra, 650-467-0842
or
Investor Contact:
Loren Kalm, 650-225-3217
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIBRA (emicizumab-kxwh) in Hemophilia a Without Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...